Skip to main content
Top
Published in: Journal of Translational Medicine 1/2020

Open Access 01-12-2020 | Research

Ethnicity and survival in bladder cancer: a population-based study based on the SEER database

Authors: Wei Fang, Zhi-Yan Yang, Ting-Yu Chen, Xian-Feng Shen, Chao Zhang

Published in: Journal of Translational Medicine | Issue 1/2020

Login to get access

Abstract

Background

Bladder cancer is the most common cancer in the urinary system and the fourth most common cancer in males. This study aimed to examine differences in the survival of bladder cancer patients of different ethnicities.

Method

We used the SEER database to obtain data pertaining to bladder cancer patients from 2010 to 2015. Univariate and multivariate Cox proportional hazards regression analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between ethnicity and death. Kaplan–Meier survival and nomogram analyses were used to compare survival differences among patients with different ethnicities.

Results

Among 101,364 bladder cancer patients, 90,910 were white, 5893 were black, 337 were American Indian/Alaska Native (AIAN), and 4224 were Asian or Pacific Islander (API). Our multivariate analysis identified differences between different ethnicities. Compared to the API group, the AIAN (HR = 1.31, 95% CI = 1.09–1.57, P < 0.001), black (HR = 1.56, 95% CI = 1.46–1.67, P < 0.001), and white (HR = 1.18, 95% CI = 1.12–1.25, P < 0.001) groups showed lower survival probabilities. Based on data from all Kaplan–Meier survival curves, there was no significant difference in survival between the black and AIAN groups, but the survival of these two races was worse than that of the white and API groups. We also used a nomogram to estimate patient survival and validated its predictive value.

Conclusion

Our results suggest that ethnic differences exist in patients with bladder cancer, that the survival of black and AIAN bladder cancer patients is worse than that of other ethnicities and that the survival of API patients is the best. The significant prognostic factors of overall survival, which include age, sex, ethnicity, summary stage, American Joint Committee on Cancer stage, surgery type, and histologic type, should be applied to bladder cancer patient prognostication.
Literature
2.
go back to reference Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010;60:244–72.PubMedCrossRef Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010;60:244–72.PubMedCrossRef
3.
go back to reference Siegel RL, Miller KD. Cancer statistics. 2019;2019(69):7–34. Siegel RL, Miller KD. Cancer statistics. 2019;2019(69):7–34.
4.
go back to reference Morrison AS, Proppe KH, Verhoek WG, Aoki K, Leck I, Ohno Y, et al. Histologic features of bladder cancer in Boston, USA, Manchester, UK, and Nagoya, Japan. Int J Cancer. 2010;30:701–5.CrossRef Morrison AS, Proppe KH, Verhoek WG, Aoki K, Leck I, Ohno Y, et al. Histologic features of bladder cancer in Boston, USA, Manchester, UK, and Nagoya, Japan. Int J Cancer. 2010;30:701–5.CrossRef
6.
go back to reference Shephard EA, Stapley S, Neal RD, Rose P, Walter FM, Hamilton WT. Clinical features of bladder cancer in primary care. Br J Gen Pract. 2012;62:e598–604.PubMedPubMedCentralCrossRef Shephard EA, Stapley S, Neal RD, Rose P, Walter FM, Hamilton WT. Clinical features of bladder cancer in primary care. Br J Gen Pract. 2012;62:e598–604.PubMedPubMedCentralCrossRef
7.
go back to reference Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66:253–62.PubMedCrossRef Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66:253–62.PubMedCrossRef
8.
go back to reference Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80:717–23.PubMed Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80:717–23.PubMed
10.
go back to reference Brenner DR, Ruan Y, Shaw E, O’Sullivan D, Poirier AE, Heer E, et al. Age-standardized cancer-incidence trends in Canada, 1971–2015. CMAJ. 2019;191:E1262–73.PubMedPubMedCentralCrossRef Brenner DR, Ruan Y, Shaw E, O’Sullivan D, Poirier AE, Heer E, et al. Age-standardized cancer-incidence trends in Canada, 1971–2015. CMAJ. 2019;191:E1262–73.PubMedPubMedCentralCrossRef
11.
go back to reference Al Hussein Al Awamlh B, Shoag JE, Ravikumar V, Posada L, Taylor BL, van der Mijn JC, et al. Association of smoking and death from genitourinary malignancies: analysis of the National Longitudinal Mortality Study. J Urol. 2019;202:1248–54.PubMedCrossRef Al Hussein Al Awamlh B, Shoag JE, Ravikumar V, Posada L, Taylor BL, van der Mijn JC, et al. Association of smoking and death from genitourinary malignancies: analysis of the National Longitudinal Mortality Study. J Urol. 2019;202:1248–54.PubMedCrossRef
12.
go back to reference Khan KM, Chakraborty R, Bundschuh J, Bhattacharya P, Parvez F. Health effects of arsenic exposure in Latin America: an overview of the past eight years of research. Sci Total Environ. 2019;710:136071.PubMedCrossRefPubMedCentral Khan KM, Chakraborty R, Bundschuh J, Bhattacharya P, Parvez F. Health effects of arsenic exposure in Latin America: an overview of the past eight years of research. Sci Total Environ. 2019;710:136071.PubMedCrossRefPubMedCentral
13.
go back to reference Zuzolo D, Cicchella D, Demetriades A, Birke M, Albanese S, Dinelli E, et al. Arsenic: geochemical distribution and age-related health risk in Italy. Environ Res. 2019;182:109076.PubMedCrossRef Zuzolo D, Cicchella D, Demetriades A, Birke M, Albanese S, Dinelli E, et al. Arsenic: geochemical distribution and age-related health risk in Italy. Environ Res. 2019;182:109076.PubMedCrossRef
14.
go back to reference Trinh QD, Hong F, Halpenny B, Epstein M, Berry DL. Racial/ethnicity differences in endorsing influential factors for prostate cancer treatment choice: an analysis of data from the personal patient profile-prostate (P3P) I and II trials. Urol Oncol. 2019;38:78.PubMed Trinh QD, Hong F, Halpenny B, Epstein M, Berry DL. Racial/ethnicity differences in endorsing influential factors for prostate cancer treatment choice: an analysis of data from the personal patient profile-prostate (P3P) I and II trials. Urol Oncol. 2019;38:78.PubMed
15.
go back to reference Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69:300–10.PubMedCrossRef Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69:300–10.PubMedCrossRef
16.
go back to reference Okada Y, Hanada M, Sugiura Y. Bladder cancer and smoking. Br Med J. 1964;1:649–50.PubMed Okada Y, Hanada M, Sugiura Y. Bladder cancer and smoking. Br Med J. 1964;1:649–50.PubMed
17.
go back to reference Hogan TF, Lamm DL, Riggs DR, Ducatman AM. Smoking and bladder cancer. W V Med J. 2001;97:29–31.PubMed Hogan TF, Lamm DL, Riggs DR, Ducatman AM. Smoking and bladder cancer. W V Med J. 2001;97:29–31.PubMed
18.
go back to reference Bates MN, Smith AH, Cantor KP. Case-control study of bladder cancer and arsenic in drinking water. Am J Epidemiol. 1995;141:523–30.PubMedCrossRef Bates MN, Smith AH, Cantor KP. Case-control study of bladder cancer and arsenic in drinking water. Am J Epidemiol. 1995;141:523–30.PubMedCrossRef
19.
go back to reference Wu XC, Yu Q, Andrews PA, Ranganath P, Qiao B, Ajani U, et al. Comparisons of directly coded SEER summary stage 2000 and collaborative staging derived SEER summary stage 2000. J Regist Manag. 2010;37:137–40. Wu XC, Yu Q, Andrews PA, Ranganath P, Qiao B, Ajani U, et al. Comparisons of directly coded SEER summary stage 2000 and collaborative staging derived SEER summary stage 2000. J Regist Manag. 2010;37:137–40.
20.
go back to reference Egner JR. AJCC cancer staging manual. JAMA. 2010;304:1726–7. Egner JR. AJCC cancer staging manual. JAMA. 2010;304:1726–7.
21.
go back to reference Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, et al. AJCC cancer staging manual. JAMA. 2010;304:1726–7.CrossRef Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, et al. AJCC cancer staging manual. JAMA. 2010;304:1726–7.CrossRef
23.
go back to reference Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol Semin Orig Investig. 2004;22:86–92. Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol Semin Orig Investig. 2004;22:86–92.
24.
go back to reference Zhang Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013;31:287–304.PubMedCrossRef Zhang Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013;31:287–304.PubMedCrossRef
25.
go back to reference Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, et al. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst. 2001;93:538–45.PubMedCrossRef Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, et al. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst. 2001;93:538–45.PubMedCrossRef
26.
go back to reference Freedman ND, Silverman DT, Hollenbeck AR, Arthur S, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737–45.PubMedPubMedCentralCrossRef Freedman ND, Silverman DT, Hollenbeck AR, Arthur S, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737–45.PubMedPubMedCentralCrossRef
27.
go back to reference Gaertner RR, Trpeski L, Johnson KC. A case-control study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control. 2004;15:1007–19.PubMedCrossRef Gaertner RR, Trpeski L, Johnson KC. A case-control study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control. 2004;15:1007–19.PubMedCrossRef
28.
go back to reference Malaguarnera L, Cristaldi E, Malaguarnera M. The role of immunity in elderly cancer. Crit Rev Oncol Hematol. 2010;74:40–60.PubMedCrossRef Malaguarnera L, Cristaldi E, Malaguarnera M. The role of immunity in elderly cancer. Crit Rev Oncol Hematol. 2010;74:40–60.PubMedCrossRef
29.
go back to reference Serrano M, Blasco MA. Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol. 2007;8:715.PubMedCrossRef Serrano M, Blasco MA. Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol. 2007;8:715.PubMedCrossRef
30.
go back to reference Ja T, Ga K. Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol. 2009;6:135–44. Ja T, Ga K. Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol. 2009;6:135–44.
31.
32.
go back to reference Vasto S, Malavolta M, Pawelec G. Age and immunity. Immun Ageing. 2006;3:1–6.CrossRef Vasto S, Malavolta M, Pawelec G. Age and immunity. Immun Ageing. 2006;3:1–6.CrossRef
33.
go back to reference Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ. Age-conditional probabilities of developing cancer. Stat Med. 2003;22:12.CrossRef Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ. Age-conditional probabilities of developing cancer. Stat Med. 2003;22:12.CrossRef
34.
go back to reference Alves TP, Lewis J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. Clin Nephrol. 2010;74:72–7. Alves TP, Lewis J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. Clin Nephrol. 2010;74:72–7.
35.
go back to reference Jolly SE, Burrows NR, Chen SC, Li S, Jurkovitz CT, Norris KC, et al. Racial and ethnic differences in mortality among individuals with chronic kidney disease: results from the Kidney Early Evaluation Program (KEEP). Clin J Am Soc Nephrol. 2011;6:1858–65.PubMedPubMedCentralCrossRef Jolly SE, Burrows NR, Chen SC, Li S, Jurkovitz CT, Norris KC, et al. Racial and ethnic differences in mortality among individuals with chronic kidney disease: results from the Kidney Early Evaluation Program (KEEP). Clin J Am Soc Nephrol. 2011;6:1858–65.PubMedPubMedCentralCrossRef
36.
go back to reference Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Landgren O. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501–6.PubMedPubMedCentralCrossRef Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Landgren O. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501–6.PubMedPubMedCentralCrossRef
37.
go back to reference Deshpande AD, Jeffe DB, Gnerlich J, Iqbal AZ, Thummalakunta A, Margenthaler JA. Racial disparities in breast cancer survival: an analysis by age and stage. J Surg Res. 2009;153:105–13.PubMedCrossRef Deshpande AD, Jeffe DB, Gnerlich J, Iqbal AZ, Thummalakunta A, Margenthaler JA. Racial disparities in breast cancer survival: an analysis by age and stage. J Surg Res. 2009;153:105–13.PubMedCrossRef
38.
go back to reference Kc D, Hr H, Sc H. Bladder Cancer: diagnosis and Treatment. Am Fam Physician. 2017;96:507–14. Kc D, Hr H, Sc H. Bladder Cancer: diagnosis and Treatment. Am Fam Physician. 2017;96:507–14.
39.
go back to reference Del Pozo Jimenez G, Herranz Amo F, Arranz Arija JA, Rodriguez Fernandez E, Subira Rios D, Lledo Garcia E, et al. Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy. Actas Urol Esp. 2019;44:94–102.PubMedCrossRef Del Pozo Jimenez G, Herranz Amo F, Arranz Arija JA, Rodriguez Fernandez E, Subira Rios D, Lledo Garcia E, et al. Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy. Actas Urol Esp. 2019;44:94–102.PubMedCrossRef
40.
go back to reference Jue JS, Koru-Sengul T, Miao F, Kroeger ZA, Moore KJ, Alameddine M, et al. Timing of adjuvant chemotherapy and overall survival following radical cystectomy. Urol Oncol. 2019;38:75.e15–75.e22.CrossRef Jue JS, Koru-Sengul T, Miao F, Kroeger ZA, Moore KJ, Alameddine M, et al. Timing of adjuvant chemotherapy and overall survival following radical cystectomy. Urol Oncol. 2019;38:75.e15–75.e22.CrossRef
41.
go back to reference Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–507.PubMedCrossRef Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–507.PubMedCrossRef
42.
go back to reference Wang F, Zhang H, Wen J, Zhou J, Liu Y, Cheng B, et al. Nomograms forecasting long-term overall and cancer-specific survival of patients with oral squamous cell carcinoma. Cancer Med. 2018;7:943.PubMedPubMedCentralCrossRef Wang F, Zhang H, Wen J, Zhou J, Liu Y, Cheng B, et al. Nomograms forecasting long-term overall and cancer-specific survival of patients with oral squamous cell carcinoma. Cancer Med. 2018;7:943.PubMedPubMedCentralCrossRef
43.
go back to reference Byers TE, Wolf HJ, Bauer KR, Bolickaldrich S, Chen VW, Finch JL, et al. The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer. 2010;113:582–91.CrossRef Byers TE, Wolf HJ, Bauer KR, Bolickaldrich S, Chen VW, Finch JL, et al. The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer. 2010;113:582–91.CrossRef
44.
go back to reference Morioka M, Jo Y, Furukawa Y, Kinugawa K, Sone A, Matsuki T, et al. Prognostic factors for survival and bladder recurrence in transitional cell carcinoma of the upper urinary tract. Int J Urol. 2010;8:366–73.CrossRef Morioka M, Jo Y, Furukawa Y, Kinugawa K, Sone A, Matsuki T, et al. Prognostic factors for survival and bladder recurrence in transitional cell carcinoma of the upper urinary tract. Int J Urol. 2010;8:366–73.CrossRef
45.
go back to reference Siemens DR, Mackillop WJ, Peng Y, Berman D, Elharram A, Rhee J, et al. Processes of Care and the impact of surgical volumes on cancer-specific survival: a population-based study in bladder cancer. Urology. 2014;84:1049–57.PubMedCrossRef Siemens DR, Mackillop WJ, Peng Y, Berman D, Elharram A, Rhee J, et al. Processes of Care and the impact of surgical volumes on cancer-specific survival: a population-based study in bladder cancer. Urology. 2014;84:1049–57.PubMedCrossRef
Metadata
Title
Ethnicity and survival in bladder cancer: a population-based study based on the SEER database
Authors
Wei Fang
Zhi-Yan Yang
Ting-Yu Chen
Xian-Feng Shen
Chao Zhang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2020
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-020-02308-w

Other articles of this Issue 1/2020

Journal of Translational Medicine 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine